Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 653
Filtrar
1.
J Oncol Pharm Pract ; 26(1): 175-186, 2020 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-31554471

RESUMO

Gender disparity exists in leadership roles within healthcare. While the majority of the healthcare workforce is comprised of women, significantly fewer women occupy leadership positions, particularly at executive and board levels. As the field of oncology pharmacy continues to rapidly expand and evolve, an assessment of the current state of women in oncology pharmacy leadership roles is vital to the growth and development of the profession. In the fall of 2017, the Hematology/Oncology Pharmacy Association (HOPA) hosted a summit to explore leadership issues facing women in oncology pharmacy which have the potential to affect our membership and our profession. This meeting included invited participants from across the fields of oncology and pharmacy and was part of HOPA's strategic leadership initiative developed through the work of the HOPA Leadership Development Committee in 2016. This promotes a primary goal of HOPA, which is to support oncology pharmacists as they assume leadership roles within their practices and within healthcare to assure oncology pharmacy is integrated into cancer care. The purpose of this white paper is to (1) summarize key issues that were identified through a membership survey; (2) review ongoing efforts to address the needs of female oncology pharmacists in leadership development; (3) serve as a call to action for individuals and professional organizations to assist with and disseminate these efforts and highlight available resources, and (4) to provide practical steps to meet the needs of individuals, training programs, and institutions/employers.


Assuntos
Liderança , Neoplasias/tratamento farmacológico , Farmacêuticos/tendências , Farmácia/tendências , Sexismo/tendências , Feminino , Humanos , Assistência Farmacêutica/tendências , Farmácia/métodos , Sexismo/prevenção & controle
3.
Yakugaku Zasshi ; 139(4): 525-527, 2019.
Artigo em Japonês | MEDLINE | ID: mdl-30930381

RESUMO

About two years have passed since the formal establishment of the category "family pharmacist" in Japan's revision of dispensing fees. In the pharmacy vision for patients, many problems were raised among the category of "family pharmacists" or "family pharmacies". Furthermore, in the future restructuring of pharmacy practices, by 2025 all pharmacies are to serve as "family pharmacies", and by 2035 they will exercise their family pharmacy function in daily living areas. In order to demonstrate the "family function", home medical care and outreach type health support etc. will be required, not only from conventional pharmacy work but also in outside (off-site) pharmacy activities. Therefore, future pharmacies need to gain the confidence of their local communities, such as in active collaboration with multi-occupational physicians and healthcare providers, work with multi-occupations in general, participation in local activities, and so on. Therefore, I would like to introduce activities that I am actually doing to this end, such as at-home activities, community activities and cooperation with multiple occupations.


Assuntos
Seguro de Serviços Farmacêuticos , Farmacêuticos , Farmácia , Serviços de Saúde Comunitária/tendências , Pessoal de Saúde , Serviços de Assistência Domiciliar/tendências , Humanos , Comunicação Interdisciplinar , Colaboração Intersetorial , Japão , Farmácia/tendências , Médicos , Atenção Primária à Saúde/tendências
5.
Am J Pharm Educ ; 83(1): 7051, 2019 02.
Artigo em Inglês | MEDLINE | ID: mdl-30894775

RESUMO

This commentary is an observation of longitudinal trends in national data on the pharmacist workforce and pharmacy education. Data indicate seismic shifts in supply and demand, from critical shortage to imminent oversupply. The change in the profession to employing more patient-care focused jobs has been observed as slow and minimal, although academia has focused on the clinical training and rapidly increased enrollments. Pharmacy is on the brink of transforming the profession, but several important changes are still required to alter the current trajectories of supply and demand. Pharmacy schools, associations, and employers must devote all energies to immediate and significant actions that tip the balance in favor of pharmacists of the future.


Assuntos
Educação em Farmácia/tendências , Farmacêuticos/tendências , Recursos Humanos/tendências , Assistência à Saúde/tendências , Emprego/tendências , Humanos , Estudos Longitudinais , Farmácia/tendências , Faculdades de Farmácia/tendências
8.
Ann Pharm Fr ; 77(1): 1-14, 2019 Jan.
Artigo em Francês | MEDLINE | ID: mdl-30636676

RESUMO

There are several indicators to evaluate the impact of the scientific publication in pharmacy. Given their number, complexity, heterogeneity, strengths and weaknesses, we believe that pharmacists are not sufficiently familiar with these indicators. The main objective is to present an inventory of available indicator to measure the research impact. PubMed, GoogleScholar and Google were interviewed in October 2017 from the following terms: bibliométrique/bibliometrics, facteur d'impact/impact factor, impact de citations/citation impact, revue/journal, chercheur/researcher, article, indicateur/indicator, score. For each identified indicator, the following variables were extracted: name, calculation method, calculation time window, data sources considered, access conditions, inclusion of self-citation, strengths and weaknesses. A total of 15 indicators were included: seven for journals, four for researchers and four for articles. Among them two are non-bibliometric indicators: the Altmetric attention score, the RGscore and one other indicator deriving from the impact factor: the SIGAPS indicator developed to finance the research activity of French hospitals. Of the 12 bibliometric indicators, nine include self-citation. All involve forces (e.g. exclusion of editorials, letters, free access) and weaknesses (e.g. self-citations included, time window too short, disciplinary indistinction). There is no indicator with no weaknesses and pharmacists should be able to understand their strengths and weaknesses.


Assuntos
Bibliometria , Publicações Periódicas como Assunto/normas , Farmácia/tendências , Pesquisadores/normas , Pesquisa , Fator de Impacto de Revistas , Farmácia/normas
10.
Pharm. care Esp ; 21(3): 157-158, 2019.
Artigo em Espanhol | IBECS | ID: ibc-185109

RESUMO

No disponible


Assuntos
Humanos , Fundações/tendências , Farmácia/tendências , Espanha
11.
Am J Pharm Educ ; 82(6): 6652, 2018 08.
Artigo em Inglês | MEDLINE | ID: mdl-30181675

RESUMO

As precision medicine research and its clinical applications continue to advance, it is critical for pharmacists to be involved in these developments to deliver optimal, tailored drug therapies for patients. To ensure pharmacists remain leaders in the field, the annual Pharmaceutical Sciences Conference convened by the University of North Carolina at Chapel Hill Eshelman School of Pharmacy focused on the role of pharmacy within precision medicine. This is a summary of the conference, highlighting the major challenges and solutions that will help advance individualized pharmacological methods within practice and research.


Assuntos
Educação em Farmácia/métodos , Educação em Farmácia/tendências , Farmácia/métodos , Farmácia/tendências , Medicina de Precisão/métodos , Medicina de Precisão/tendências , Congressos como Assunto , Assistência à Saúde/métodos , Humanos , Farmacêuticos
12.
Ars pharm ; 59(3): 153-161, jul.-sept. 2018. tab, graf
Artigo em Espanhol | IBECS | ID: ibc-177731

RESUMO

Antecedentes y objetivo: La gravedad e inestabilidad de los pacientes, junto con el alto grado de complejidad de la medicación, hacen de las unidades de cuidados intensivos (UCI) un área crítica de problemas relacionados con la medicación. El objetivo de nuestro estudio fue analizar y evaluar la actividad clínica realizada por el farmacéutico clínico integrado en una UCI y conocer la opinión del personal. Material y método: Estudio descriptivo, prospectivo, de 42 meses de duración. El farmacéutico se integró en la actividad diaria del equipo multidisciplinar de una UCI de 12 camas perteneciente al Servicio de Anestesiología y Reanimación. Se registraron todas las intervenciones farmacoterapéuticas (IF) realizadas, el grado de aceptación, el método de comunicación y destinatario de la intervención, así como la evaluación clínica de las intervenciones aceptadas. Posteriormente, se realizó una encuesta al personal de la unidad sobre la seguridad del paciente y la influencia de la integración del farmacéutico en la unidad. Resultados: Se realizaron un total de 2399 IF con un 97,0% de aceptación. De estas, las mayoritarias fueron las relacionadas con la posología (37,8%) y las consultas al farmacéutico (25,7%). De las IF aceptadas, el 53,7% influyeron sobre la eficacia del tratamiento farmacológico y el 35,1% sobre la tolerancia. En la encuesta realizada al personal de la unidad para valorar la percepción de la integración del farmacéutico se obtuvo una valoración global de de 8,58 ± 1,40 sobre 10. Conclusiones: El farmacéutico hospitalario integrado en el equipo multidisciplinar de UCI puede aportar un valor añadido al proceso farmacoterapéutico del paciente crítico


Background and objective: The severity and instability of the patients, together with the high degree of complexity of the medication, make the intensive care units (ICU) a critical area of problems related to medication. The aim of our study was to analyze and assess the activity performed by the clinical pharmacist integrated in an ICU and to know the opinion of the staff about it. Material and method: A 42 month descriptive and prospective study was conducted. The pharmacist was integrated into the daily activity of the multidisciplinary team of a 12-bed ICU belonging to the Anaesthesiology and Resuscitation Department. Every pharmacotherapeutic intervention (PI) carried out, the degree of acceptance, the method of communication and the receiver of the intervention, as well as the clinical evaluation of the accepted interventions were recorded. Subsequently, a survey was carried out to the staff of the unit on the patient's safety and the influence of the integration of the pharmacist in the unit. Results: A total of 2399 PIs were carried out with a 97.0% of acceptance. Of these, most were those related to posology (37.8%) and consultations with the pharmacist (25.7%). Among the accepted PIs, 53.7% had an influence on the efficacy of drug therapy, and 35.1% on treatment tolerance. In the survey to the unit's staff in order to assess the perception of the pharmacist's integration, an overall assessment of 8.58 ± 1.40 out of 10 was obtained. Conclusions: The hospital pharmacist integrated in the ICU multidisciplinary team can add value to the pharmacotherapeutic process of the critical patient


Assuntos
Humanos , Assistência ao Paciente , Estado Terminal , Assistência Farmacêutica/métodos , Cuidados Críticos , Farmácia/tendências , Assistência Farmacêutica , Estudos Prospectivos , Segurança do Paciente , Unidades de Terapia Intensiva
13.
Consult Pharm ; 33(8): 414-421, 2018 Aug 01.
Artigo em Inglês | MEDLINE | ID: mdl-30068435

RESUMO

A wide range of changes are in the future for health care: value-based reimbursement, delivery of integrated services, the continued breakdown of silos, and interoperability maximizing communication/information exchange. The American Society of Consultant Pharmacists recently held a conference focusing on key innovations in post-acute/long-term/senior care and how pharmacists can function successfully in this new paradigm in ways that promote quality medication management, address polypharmacy, improve patients' quality of life, reduce costs, and eliminate avoidable readmissions.


Assuntos
Previsões , Farmacêuticos , Farmácia/tendências , Conduta do Tratamento Medicamentoso
17.
J Drugs Dermatol ; 17(6): 599-600, 2018 Jun 01.
Artigo em Inglês | MEDLINE | ID: mdl-29879246

RESUMO

Acne vulgaris (AV) is a very common inflammatory facial disorder that is complex in its pathophysiology, heterogenous in clinical presentation, and affects children and adults of all ethnicities, races, and skin types.


Assuntos
Acne Vulgar/tratamento farmacológico , Fármacos Dermatológicos/administração & dosagem , Papel Profissional , Responsabilidade Social , Acne Vulgar/diagnóstico , Acne Vulgar/economia , Administração Tópica , Prescrições de Medicamentos/economia , Humanos , Cobertura do Seguro/economia , Cobertura do Seguro/tendências , Farmácia/tendências , Resultado do Tratamento
18.
J Manag Care Spec Pharm ; 24(4-a Suppl): S1-S116, 2018 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-29629623

RESUMO

The AMCP Managed Care & Specialty Pharmacy Annual Meeting 2018 in Boston, Massachusetts, is expected to attract more than 3,800 managed care pharmacists and other health care professionals who manage and evaluate drug therapies, develop and manage networks, and work with medical managers and information specialists to improve the care of all individuals enrolled in managed care programs. The AMCP Abstracts program provides a forum through which authors can share their insights and outcomes of advanced managed care practice. Abstracts are presented as posters on Wednesday, April 25, from 12:30 pm to 2:30 pm. Posters will also be displayed on Tuesday, April 24, from 5:45 pm to 7:30 pm, and on Thursday, April 26, from 9:30 am to 11:00 am. Podium presentations for the Platinum award-winning abstracts are Thursday, April 26, from 8:00 am to 9:15 am. Professional abstracts that have been reviewed are published in the Journal of Managed Care & Specialty Pharmacy's Meeting Abstracts supplement.


Assuntos
Congressos como Assunto , Programas de Assistência Gerenciada , Assistência Farmacêutica , Farmacêuticos , Farmácia , /métodos , Congressos como Assunto/tendências , Humanos , Programas de Assistência Gerenciada/tendências , Massachusetts , Assistência Farmacêutica/tendências , Farmacêuticos/tendências , Farmácia/tendências
19.
J Manag Care Spec Pharm ; 24(3): 304-310, 2018 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-29460679

RESUMO

Patient-reported outcomes (PROs), which provide a direct measure of a patient's health status or treatment preferences, represent a key component of the shift toward patient-centered health care. PROs can measure the state of a patient's disease-specific and overall health throughout the care continuum, enabling them to have a variety of uses for key health care stakeholders. Currently, PROs are used in drug development, aligning patient and clinician goals in care, quality-of-care measures, and coverage and reimbursement decisions. While there have been significant strides by key health care stakeholders to further the development and use of PROs, there are a number of challenges limiting more widespread use. In light of these current challenges and the potential for PROs to improve health care quality and value, on October 19, 2017, the Academy of Managed Care Pharmacy convened a forum of key stakeholders representing patients, payers, providers, government, and pharmaceutical companies to discuss and identify solutions to the current challenges and barriers to further use of PROs. These discussions informed the development of participants' ideal future state in which PROs maximize the goals of all health care stakeholders and the actionable steps required to make the future state a reality. While stakeholders shared unique perspectives throughout the forum, they had consensus on 2 overarching issues: the importance of PROs in defining value, improving patient care, and implementing value-based payment models and the need for strong organizational and operational systems to achieve optimal adoption and use. Participants identified several key challenges in PRO use and adoption: achieving a representative patient population, inclusion of PRO data in medication labels, the necessity for both standardized and customizable PROs, and operational and organizational barriers to collecting and analyzing PROs. To overcome these challenges, participants recommended that manufacturers should engage key stakeholders early and throughout the drug development process to ensure the most valid and representative PROs and patient populations will be included. To streamline the PRO collection process, participants suggested engaging pharmacists and other providers who may have more frequent interaction with patients. Participants also recommended that PRO collection and analysis should use common technology platforms, streamline components of clinician care to reduce workflow, and be integrated with claims data to provider payers a better understanding of patient health in real time. Finally, additional work should be done to develop patient-reported outcome measures that contain relevant measures for all healthcare stakeholders. While significant challenges remain in PRO development and adoption, participants agreed that greater use can only be achieved through collaboration and patient-centered care. DISCLOSURES: The AMCP Partnership Forum titled "Improving Quality, Value, and Outcomes with Patient-Reported Outcomes" and the development of this proceedings report were supported by Amgen, Boehringer Ingelheim Pharmaceuticals, Genentech, GlaxoSmithKline, Novartis Pharmaceuticals, Novo Nordisk, Precision for Value, Premier, Sanofi, Takeda Pharmaceuticals USA, and Xcenda.


Assuntos
Academias e Institutos/tendências , Programas de Assistência Gerenciada/tendências , Medidas de Resultados Relatados pelo Paciente , Farmácia/tendências , Qualidade da Assistência à Saúde/tendências , Academias e Institutos/normas , Humanos , Programas de Assistência Gerenciada/normas , Farmácia/normas , Qualidade da Assistência à Saúde/normas
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA